CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,094,704 | +56.4% | 46,149 | +40.1% | 0.49% | +46.3% |
| Q2 2023 | $1,339,052 | 0.0% | 32,941 | 0.0% | 0.34% | 0.0% |
| Q1 2023 | $1,339,052 | 0.0% | 32,941 | 0.0% | 0.34% | 0.0% |
| Q4 2022 | $1,339,052 | -32.0% | 32,941 | +9.4% | 0.34% | -35.8% |
| Q3 2022 | $1,968,000 | +20.4% | 30,118 | +11.9% | 0.52% | +16.8% |
| Q2 2022 | $1,635,000 | +11.7% | 26,905 | +15.4% | 0.45% | +40.6% |
| Q1 2022 | $1,464,000 | -14.0% | 23,324 | +3.8% | 0.32% | -15.4% |
| Q4 2021 | $1,703,000 | -38.9% | 22,472 | -9.7% | 0.38% | -43.1% |
| Q3 2021 | $2,786,000 | -32.4% | 24,891 | -2.2% | 0.66% | -31.7% |
| Q2 2021 | $4,122,000 | +305.7% | 25,460 | +205.2% | 0.97% | +273.7% |
| Q1 2021 | $1,016,000 | +28.1% | 8,342 | +61.1% | 0.26% | +29.5% |
| Q4 2020 | $793,000 | – | 5,178 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |